UK Antitrust Authority: Actavis Inflated Prices of Hydrocortisone

International Pharmaceutical Regulatory Monitor
A A
UK’s antitrust agency has accused Actavis of breaching competition law by raising the price of generic hydrocortisone tablets for Addison’s disease by more than 12,000 percent since 2008.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor